Wave Life Sciences Ltd

For the period ended Jun 30, 2024. Filed Aug 8, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 8, 2024

WVE$3.41-2.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Unaudited Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except share and per share amounts)

	Three Months Ended June 30,		Six Months Ended June 30,
	2024	2023	2024	2023
Revenue	$19,692	$22,106	$32,230	$35,035
Operating expenses:
Research and development	40,393	33,314	73,840	64,293
General and administrative	14,296	12,265	27,845	24,500
Total operating expenses	54,689	45,579	101,685	88,793
Loss from operations	(34,997)	(23,473)	(69,455)	(53,758)
Other income, net:
Dividend income and interest income	2,092	2,251	4,627	4,124
Other income (expense), net	(18)	118	347	1,125
Total other income, net	2,074	2,369	4,974	5,249
Loss before income taxes	(32,923)	(21,104)	(64,481)	(48,509)
Income tax benefit (provision)	—	—	—	—
Net loss	$(32,923)	$(21,104)	$(64,481)	$(48,509)
Net loss per share attributable to ordinary shareholders—basic and diluted	$(0.25)	$(0.20)	$(0.50)	$(0.47)
Weighted-average ordinary shares used in computing net loss per share attributable to ordinary shareholders—basic and diluted	129,527,003	105,462,414	129,399,340	103,768,971
Other comprehensive loss:
Net loss	$(32,923)	$(21,104)	$(64,481)	$(48,509)
Foreign currency translation	(81)	(100)	(155)	(121)
Comprehensive loss	$(33,004)	$(21,204)	$(64,636)	$(48,630)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.